Literature DB >> 29452296

Development and Persistence of Suspected Neuropathic Pain After Total Knee Arthroplasty in Individuals With Osteoarthritis.

Matthew Fitzsimmons1, Eloise Carr2, Linda Woodhouse3, Geoff P Bostick4.   

Abstract

BACKGROUND: Despite the effectiveness of total knee arthroplasty (TKA) for osteoarthritis (OA), up to 20% will report knee pain 1 year after surgery. One possible reason is the development of neuropathic pain before or after TKA.
OBJECTIVE: To longitudinally describe suspected neuropathic pain in patients pre- and post-TKA and to explore relations between pre-TKA suspected neuropathic pain and post-TKA outcomes.
DESIGN: Prospective observational study.
SETTING: Participants were recruited from orthopedic surgery clinics prior to inpatient elective primary TKA. PARTICIPANTS: Convenience sample of 135 patients were assessed for eligibility; 99 were enrolled and 74 completed the 6-month follow-up.
METHODS: Participants completed the Self-Leeds Assessment of Neuropathic Symptoms and Signs (S-LANSS) and outcome measures at baseline (pre-TKA) and 1 and 6 months post-TKA by postal survey. Demographic variables included age, gender, and comorbidities. Descriptive statistics were calculated for the presence of suspected neuropathic pain at each assessment and course of outcomes for various suspected neuropathic pain trajectories. Further, t-tests were used to compare outcomes between those with and without suspected neuropathic pain at each assessment. Multiple linear regressions assessed the relationship between baseline suspected neuropathic pain and 6-month outcomes. MAIN OUTCOME MEASUREMENTS: Intermittent and Constant Osteoarthritis Pain (ICOAP), Pain Catastrophizing Scale (PCS), and the Patient Health Questionnaire (PHQ-9) for depression.
RESULTS: Suspected neuropathic pain was present in 35.5% of pre-TKA patients, 39.0% at 1 month, and 23.6% at 6 months post-TKA. Those with suspected neuropathic pain had higher scores for ICOAP total pain (P = .05), pain catastrophizing (P < .01), and depression (P < .01) at each assessment. After adjusting for potential confounding, pre-TKA suspected neuropathic pain did not predict ICOAP total pain or PHQ-9 depression scores at 6 months.
CONCLUSIONS: Although 14% of individuals with knee OA had suspected neuropathic pain that persisted 6 months post-TKA and those with suspected neuropathic pain had higher levels of pain, catastrophizing, and depression, the clinical identification of neuropathic pain remains enigmatic. Preoperative suspected neuropathic pain, as measured by S-LANSS, may have limited prognostic value for post-TKA outcomes. LEVEL OF EVIDENCE: II.
Copyright © 2018 American Academy of Physical Medicine and Rehabilitation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 29452296     DOI: 10.1016/j.pmrj.2018.01.010

Source DB:  PubMed          Journal:  PM R        ISSN: 1934-1482            Impact factor:   2.298


  4 in total

1.  Does the Presence of Neuropathic Pain Influence the Response to Hyaluronic Acid in Patients with Knee Osteoarthritis?

Authors:  Evarice Tiendrebeogo; Magda Choueiri; Xavier Chevalier; Thierry Conrozier; Florent Eymard
Journal:  Cartilage       Date:  2020-09-10       Impact factor: 3.117

2.  High Prevalence of Pain Sensitization in Knee Osteoarthritis: A Meta-Analysis with Meta-Regression.

Authors:  Davide Previtali; Gianluigi Capone; Paolo Marchettini; Christian Candrian; Stefano Zaffagnini; Giuseppe Filardo
Journal:  Cartilage       Date:  2022 Jan-Mar       Impact factor: 3.117

3.  Functional improvement in hip pathology is related to improvement in anxiety, depression, and pain catastrophizing: an intricate link between physical and mental well-being.

Authors:  Paul Gudmundsson; Paul A Nakonezny; Jason Lin; Rebisi Owhonda; Heather Richard; Joel Wells
Journal:  BMC Musculoskelet Disord       Date:  2021-02-03       Impact factor: 2.362

4.  Possible Neuropathic Pain in Patients with Osteoarthritis of the Knee Before and After Total Knee Arthroplasty.

Authors:  Masahiro Hasegawa; Shine Tone; Yohei Naito; Akihiro Sudo
Journal:  J Pain Res       Date:  2021-09-23       Impact factor: 3.133

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.